Funds used for clinical development of the first selective TLR8 agonists
SAN DIEGO, January 12, 2010– VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension. The Series A [...]
Experienced Drug Hunters Armed with Structure-Based G Protein-Coupled Receptor (GPCR) Drug Discovery Technology From The Scripps Research Institute
SAN DIEGO, November 23, 2009– Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. The company is focused on identifying and developing best- and first-in-class GPCR therapeutic candidates through [...]
Led by OVP Venture Partners and Includes Syndicate of Corporate Investors
LA JOLLA, Calif., November 16, 2009– Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures [...]
SUNNYVALE, Calif., November 5, 2009– Cambrios Technologies Corporation, an electronic materials company commercializing ClearOhm™ coating material for producing transparent conductive films, announced today that the company has received investments totaling $14.5 million in a first closing of its Series D Financing Round. All of the company’s existing institutional preferred shareholders participated in the round, including [...]
Company Developing Novel Therapies to Treat and Prevent Respiratory Diseases
LEXINGTON, Mass., November 2, 2009– Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and [...]
